DB
NTLA icon

Danske Bank’s Intellia Therapeutics NTLA Stock Holding History

Danske Bank’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38K Hold
200
– – ﹤0.01% 952
2026
Q1 		$2.56K Sell
200
-2,500
-93% -$31.8K ﹤0.01% 970
2025
Q4 		$24.3K Sell
2,700
-200
-7% -$2.75K ﹤0.01% 1161
2025
Q3 		$50.1K Hold
2,900
– – ﹤0.01% 1019
2025
Q2 		$27.2K Buy
2,900
+2,300
+383% +$18.9K ﹤0.01% 1133
2025
Q1 		$4.27K Hold
600
– – ﹤0.01% 1190
2024
Q4 		$7K Sell
600
-4,000
-87% -$62.4K ﹤0.01% 1165
2024
Q3 		$94.5K Buy
4,600
+3,500
+318% +$80.7K ﹤0.01% 1024
2024
Q2 		$24.6K Buy
+1,100
New +$26.2K ﹤0.01% 1041

Other funds holding NTLA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Danske Bank's NTLA Position: Q2 2026 in Review

Danske Bank held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 200 shares worth $3.38K. The position accounts for ﹤0.01% of the portfolio, ranked #952.

Danske Bank first reported a position in NTLA in Q2 2024 and has held it in 9 quarters since. The position peaked at $94.5K in Q3 2024. 234 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Danske Bank held 200 shares of Intellia Therapeutics worth $3.38K as of Q2 2026.
  • Danske Bank left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #952 holding.
  • Danske Bank first reported a position in Intellia Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Danske Bank's Intellia Therapeutics position peaked at $94.5K in Q3 2024.
  • 234 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.